TG Therapeutics (TGTX) – Biotech Innovation & Global Expansion

Company Overview:
TG Therapeutics TGTX is a biotech leader focused on novel cancer and autoimmune treatments, gaining momentum as an IBD Leaderboard and IBD 50 Top 10 Growth Stock.

Key Catalysts:

Regulatory Approvals & Expansion 🌍

BRIUMVI secured approvals in Europe & the UK, unlocking new revenue streams in key markets.
Strong Profitability & Growth 💰

88.3% gross margin ensures sustainable reinvestment into R&D and future pipeline advancements.
High-Growth Stock Recognition 📊

Technical strength is validated by its inclusion in top-performing stock lists, signaling strong investor confidence.
Investment Outlook:
Bullish Case: We are bullish on TGTX above $34.00-$35.00, driven by global expansion, financial strength, and biotech leadership.
Upside Potential: Our price target is $55.00-$56.00, supported by continued innovation and market penetration.

🔥 TG Therapeutics – Pioneering the Future of Cancer Treatment. #TGTX #Biotech #GrowthStocks